A fully humanised bispecific antibody is showing promise as a treatment for relapsed/refractory B-cell lymphoma, including in patients who have received prior CAR T-cell therapy. Speaking at ASH 2019 in a plenary scientific session for selected presentations likely to be practice changing, Professor Stephen Schuster presented interim results from a phase 1/1b study of mosunetuzumab. ...
Bispecific antibody tested in relapsed/refractory B-cell lymphoma
By Mardi Chapman
10 Dec 2019